Metastasis is a major factor in the malignancy of cancers, and is often responsible for the failure of cancer treatment. Anoikis (apoptosis resulting from loss of cell–matrix interactions) has been suggested to act as a physiological barrier to metastasis; resistance to anoikis may allow survival of cancer cells during systemic circulation, thereby facilitating secondary tumour formation in distant organs1,2,3. In an attempt to identify metastasis-associated oncogenes, we designed an unbiased, genome-wide functional screen solely on the basis of anoikis suppression. Here, we report the identification of TrkB, a neurotrophic tyrosine kinase receptor4,5, as a potent and specific suppressor of caspase-associated anoikis of non-malignant epithelial cells. By activating the phosphatidylinositol-3-OH kinase/protein kinase B pathway, TrkB induced the formation of large cellular aggregates that survive and proliferate in suspension. In mice, these cells formed rapidly growing tumours that infiltrated lymphatics and blood vessels to colonize distant organs. Consistent with the ability of TrkB to suppress anoikis, metastases—whether small vessel infiltrates or large tumour nodules—contained very few apoptotic cells. These observations demonstrate the potent oncogenic effects of TrkB and uncover a specific pro-survival function that may contribute to its metastatic capacity, providing a possible explanation for the aggressive nature of human tumours that overexpress TrkB.
To perform a functional screen for suppressors of anoikis, we selected rat intestinal epithelial (RIE) cells owing to their non-malignancy and high sensitivity to anoikis (refs 6, 7; see below). Anoikis can be induced in vitro by transferring epithelial cells from standard, adhesive cell culture dishes (with a hydrophilic surface that supports cell attachment and spreading) to ultra-low cluster (ULC) plates with a covalently bound hydrogel layer that effectively inhibits cellular attachment. Shifting RIE cells from adhesive to ULC dishes resulted in massive cell death (Fig. 1a, left), which was critical in view of the desired minimal number of surviving ‘background’ cells that would represent false positives in the screen. In agreement with previous results7, oncogenic RasV12 protein effectively suppressed anoikis (Fig. 1a, right).
Upon retroviral delivery of a high-complexity pEYK retroviral complementary DNA library8, cells were brought into suspension and screened for surviving clones (Fig. 1b). Relative to control green fluorescent protein (GFP)-infected cells that died, a proportion of library-infected pools showed surviving clones (see Methods), including ‘ME-3’; this clone effectively suppressed anoikis and formed large, spheroid aggregates in suspension (Fig. 1c). Isolation and sequencing of its proviral insert revealed a full-length, wild-type cDNA encoding TrkB, a neurotrophic tyrosine kinase receptor that is required for the ontogeny, function and survival of the mammalian nervous system4,5 and other cell types9,10,11,12. Interestingly, neurite development and outgrowth may represent processes that particularly rely on adhesion-independent survival13.
To characterize the biological effects of TrkB, we generated, by retroviral delivery, pools of epithelial cells stably expressing TrkB, its primary ligand (brain-derived neurotrophic factor (BDNF))14,15, or both (Supplementary Fig. S1a). On adhesive plates, TrkB, but not BDNF, disrupted epithelial cell organization, which was aggravated by ligand co-expression, resulting in complete loss of cell–cell contact and, upon reaching confluency, in continued proliferation as spheroids in suspension (Fig. 1d, Supplementary Fig. S1b, c).
To confirm that TrkB suppresses anoikis, we followed the fate of TrkB-expressing epithelial cells in suspension. In ULC dishes, both empty-vector and BDNF-expressing cells underwent cell death, starting at day two and leaving no surviving cells after two weeks (Fig. 1e). By contrast, TrkB effectively suppressed cell death and allowed cells to proliferate as large spheroid aggregates in suspension, explaining the identification of TrkB in the screen. Co-expression of TrkB with BDNF led to a further increase in cell number (Supplementary Fig. S1d). Similar results were obtained for murine and human epithelial cells (Supplementary Fig. S1e). The observation that the entire polyclonal TrkB-expressing cell population was resistant to anoikis argued against clonal events being due to genetic mutations. This was further supported by a soft-agar assay, which reinforced our notion that TrkB expression bypasses the need for anchorage, with virtually every TrkB-expressing cell producing a colony (Fig. 1f).
As anoikis is defined as apoptosis caused by lack of adhesion2, we examined whether it was specifically apoptosis that was prevented by TrkB. First, staining with an apoptosis-dependent fluorescent dye (3,3′-dihexyloxa-carbocyanine iodide, DiOC6(3)) showed that, in agreement with previous results6,7, RIE cells underwent apoptosis upon attachment withdrawal (Fig. 2a, left). By contrast, apoptosis was completely blocked by TrkB (Fig. 2a, right). Second, we determined by immunoblotting the protein levels of cleaved caspase-3, a primary executioner of apoptosis. Whereas no activated caspase-3 was detected in any of the cell lines when grown on adhesive dishes, it was produced by control and BDNF-expressing cells when they were brought into suspension (Fig. 2b). By contrast, cleaved caspase-3 production was completely suppressed by TrkB, regardless of the presence of TrkB's ligand. Together, these results indicate that it is apoptosis, resulting from lack of adhesion, that is effectively suppressed by TrkB.
Integrins are principal mediators of adhesion between cells and extracellular matrix proteins, including fibronectin, and they transduce signals critically required for cell survival16,17. Therefore, we examined whether TrkB-mediated resistance to anoikis depends on fibronectin, or on any other potential survival factor(s) present in cell culture serum. When TrkB-expressing cells were deprived of serum, they were partially protected from apoptosis, relative to control cells (Fig. 2c). However, BDNF-stimulated TrkB rendered cells resistant to anoikis, despite the complete absence of serum. This effect was not due to a general pro-survival function of TrkB, as TrkB, in contrast to the anti-apoptotic Bcl-2 protein, completely failed to protect adherent c-Myc-expressing fibroblasts from apoptosis resulting from serum withdrawal (Fig. 2d, e). Therefore, in untransformed epithelial cells, the BDNF–TrkB axis generates a signal that is sufficiently potent to allow, in the absence of any exogenous factors, survival in the face of a strong and specific pro-apoptotic anoikis signal.
To investigate whether TrkB directly activates survival signalling, as well as to identify its downstream targets, we first examined the potential involvement of protein kinase B (PKB; also known as AKT), which by itself is sufficient to suppress anoikis18,19. Under adherent conditions, TrkB induced production of activated, phosphorylated PKB (Fig. 2f, left). As TrkB/BDNF-expressing cells on adhesive dishes show diminished cell–cell interactions (Fig. 1d), this result demonstrates that, rather than through promoting cell–cell adhesion, TrkB directly activates the PKB survival pathway. This result, however, does not rule out the possibility that aggregate formation may contribute to survival signalling in suspension. Importantly, PKB activation was maintained in cells challenged with anoikis (Fig. 2f, right), raising the possibility that the PKB pathway mediates anoikis suppression by TrkB. Indeed, blocking PKB-dependent signalling by pharmacological inhibition of its major upstream regulator, phosphatidylinositol-3-OH kinase (PI(3)K), with LY294002 significantly interfered with TrkB-mediated survival (Fig. 2g; Supplementary Fig. S2a, b). In turn, cell death was prevented by activated PKB, excluding aspecific cytotoxic effects of LY294002, and further supporting a central role for PKB in anoikis suppression by TrkB. In line with previous data on Madine–Darby canine kidney (MDCK) cells18, PI(3)K was also sufficient to suppress anoikis, albeit to a lesser degree than TrkB (Supplementary Fig. S2c). One of the critical downstream targets of the PI(3)K/PKB pathway is p70S6K, a kinase implicated both in anoikis and lymphomagenesis18,20. However, although rapamycin (a specific inhibitor of mTOR, which is a regulator of p70S6K) blocked p70S6K phosphorylation, it completely failed to affect the survival of TrkB-expressing cells in suspension (Fig. 2h, i). Similarly, dominant interference with signalling by Rac proteins (another target of PKB), or pharmacological inhibition of MEK did not prevent suppression of anoikis by TrkB (Supplementary Fig. S2d, e). We conclude that TrkB activates PI(3)K/PKB signalling, which contributes to anoikis resistance.
The main objective of this study was to assess the feasibility of using anoikis suppression as a basis to identify metastasis-inducing (onco)genes. When non-malignant cells expressing TrkB, either alone or in conjunction with its ligand, were introduced into nude mice, they rapidly formed tumours with high efficiencies, whereas vector and BDNF-expressing cells failed to do so (Supplementary Table S1). Therefore, expression of TrkB is sufficient to convert non-malignant epithelial cells into highly tumorigenic cells.
To address whether TrkB endows epithelial cells with metastatic potential as well, we first re-engineered our cell panel to express luciferase, which allows non-invasive in vivo imaging in live mice21. Each polyclonal cell line was administered intravenously to nude mice, and outgrowth and the location of tumours was monitored. Luciferase imaging showed that, although at 90 min after injection control cells were apparently viable and had accumulated in the lungs to at least the same extent as TrkB/BDNF co-expressing cells, no luciferase signal was detectable at 6 days (Fig. 3a). Indeed, control and BDNF-expressing cells failed to form tumours within 100 days after inoculation (Fig. 3b), consistent with the hypothesis that non-malignant epithelial cells fail to survive for a prolonged period in the absence of appropriate attachment2. By contrast, TrkB-expressing epithelial cells colonized the lungs and heart, where they formed rapidly growing tumours (Fig. 3c). This phenotype was even more pronounced for TrkB/BDNF-expressing cells, which caused metastases throughout the body (Fig. 3a, c; Supplementary Fig. S3). The cooperation between TrkB and BDNF in inducing metastasis therefore recapitulated their collaboration in suppressing anoikis under low-serum conditions (which may better approximate the situation in vivo than does 10% serum; compare Fig. 2c to Fig. 3c).
Microscopic pathological analysis showed the capacity of TrkB to induce solid, non-encapsulated tumours with undifferentiated properties (Fig. 4 and Supplementary Fig. S4). The tumours showed malignant cellular characteristics, including a high mitotic index, a high nucleus:cytoplasm ratio, and notable cellular and nuclear pleomorphism. TrkB-specific immunohistochemistry showed that these tumours were able to efficiently invade both blood and lymphatic vessels in various tissues, including liver, kidney, lung and heart (Fig. 4a–f, i, j and Supplementary Fig. S4). This infiltrative character of TrkB-driven tumours was also markedly illustrated by their capacity to destruct and invade bones (Supplementary Fig. S4g–i). Furthermore, these tumours, when present as large tumour masses, were viable and proliferating, as judged by their very low apoptotic and high proliferative indices respectively (Fig. 4 g, h, k). Importantly, this viable and non-apoptotic character was retained when these tumours extended into vessels (Fig. 4i, j), conceivably contributing to their metastatic potential and consistent with our finding in vitro that TrkB suppresses anoikis. The tumours were so invasive, destructive and fast-growing that only 18 days after administration, all mice had been euthanized (Fig. 3b, Supplementary Fig. S3).
As the intravenous metastasis system precludes an assessment of the early stages of metastasis (tissue invasion and endothelial or lymphatic intravasation by disseminated tumour cells), we also introduced TrkB/BDNF co-expressing cells subcutaneously. To increase the time window in which metastasis could occur, tumours that arose within a week were surgically removed, and upon relapse mice were killed. In agreement with, and extending the results described above, pathological examination showed that the subcutaneous tumour cells had efficiently infiltrated muscles, lymphatic vessels and regional lymph nodes, eventually causing several metastases at the pleural side of the lungs (Fig. 4l–p). Together, these results demonstrate that TrkB acts as a potent oncogene that converts non-malignant epithelial cells into metastasizing tumour cells.
TrkB and BDNF are frequently overexpressed in human cancer, including pancreatic and prostate carcinomas, Wilms' tumour and neuroblastomas, particularly those with aggressive behaviour and poor prognosis22,23,24,25. Moreover, recent sequence analysis of the tyrosine kinome in colorectal cancers has shown mutations within the kinase domain of TrkB26. Although these observations have associated TrkB with cancer, it has been unclear whether deregulated TrkB can act oncogenically. We find that TrkB generates a specific and potent pro-survival signal that renders epithelial cells resistant to anoikis. This is accompanied by the acquirement of potent tumorigenic, invasive and metastatic capacities, arguing that TrkB may directly contribute to human malignancies. Although our data are consistent with the hypothesis that suppression of anoikis contributes to the acquisition of a metastatic phenotype, other properties of TrkB, including induction of invasiveness, may contribute to its aggressive tumorigenic effects.
The propensity to metastasize may be determined by the gene expression signature already present in the primary tumour27. The results presented here raise the possibility that TrkB activation may represent such an early event during multistep tumorigenesis, endowing primary cells with a wide spectrum of capacities contributing to cancer. Mainly on the basis of the overexpression of TrkB in poor-prognosis human tumours, pan-Trk-inactivating drugs are already being developed28. Our findings predict that drug-mediated inactivation of specifically TrkB may have a notable impact on the tumorigenic and metastatic capacities of human tumours with overexpressed or mutated TrkB. Finally, our results not only illustrate the feasibility of using anoikis suppression as a functional property to identify metastasis-associated oncogenes, but also show its potential use in high-throughput screens for TrkB-inhibitory cancer therapeutics.
Genome-wide retroviral cDNA screen
RIE cells were infected, in the presence of 5 µg ml-1 polybrene, with a high-complexity retroviral pEYK cDNA library8, prepared from a whole mouse embryo and propagated in Phoenix packaging cells as eight pools representing two size fractions (1–3 and >3 kilobases (kb)). Filtered (0.45 µm) viral supernatant pools representing the two size fractions were used to infect 0.75 × 106 cells each, and 2 days later, cells were collected by trypsinization and transferred to four ULC six-well cell culture dishes (Costar) in total. After 6 days, cells were transferred back to regular, adhesive tissue culture dishes, to allow anoikis-resistant cells to expand. After 10 days, cells were re-challenged with an anoikis insult, by transferring them into ULC plates. One week later, surviving colonies were isolated and transferred to 24-well adhesive plates, and allowed to expand. Then, genomic DNA was isolated and digested with either NotI or AscI, re-ligated and transformed into Escherichia coli. Plasmid DNA was isolated and transfected onto Phoenix cells. Virus supernatant was subsequently used to infect fresh RIE cells and a second-round screen was performed to validate the biological activity of the respective proviral cDNAs. Finally, proviral cDNA inserts were isolated from positive clones, shuttled and analysed by DNA sequencing. One of the anoikis-resistant clones (ME-3) contained a wild-type, full-length murine cDNA encoding TrkB, which was sub-cloned into the pBabe-puro retroviral vector. Of the 24 wells screened, 12 contained anoikis-resistant clones, sometimes several per well, giving 20 anoikis-resistant clones in total. Polymerase chain reaction (PCR) analysis for retroviral TrkB inserts showed that, in addition to ME-3, TrkB was present in seven clones (derived from four different wells). The remaining 13 clones remain to be analysed further.
A murine full-length cDNA encoding BDNF was isolated from a mouse cDNA library (Clontech) by PCR (primers available upon request), and sub-cloned into the pBabe-hygro retroviral vector.
Cell culture and in vitro assays
RIE cells were maintained in high-glucose Dulbecco's modified Eagle's Medium (DMEM) (Life Technologies) supplemented with 9% fetal bovine serum (PAA Laboratories) and antibiotics. c-Myc-expressing Rat1 fibroblasts were provided by K. Berns. Phoenix packaging cells were used to generate ecotropic retroviruses, as described29. In general, a single-infection round of 6 h was sufficient to infect at least 90% of the population. RIE cells were infected with pBabe retroviral vectors carrying selectable markers and cDNA inserts, and at 1 to 2 days post infection selected with puromycin (1.5 µg ml-1) or hygromycin (75 µg ml-1) for at least 5 days. After confirming that all mock-infected cells were dead, the cells were used in various assays.
Proliferation curves were performed with two independent cultures for each cell line, and data points were collected in triplicate, as described29.
To determine the cloning efficiency of RIE cell lines in semi-solid medium, soft agar assays were performed, as described29.
To measure apoptosis, cells were collected from either adhesive or suspension plates (both populations were subjected to trypsinization), treated with DiOC6(3) (a fluorescing dye that accumulates in mitochondria as a function of membrane potential30; Molecular Probes) in PBS for 15 min at 37 °C, and subsequently analysed by fluorescence-activated cell sorting (FACS).
Pharmacological inhibition was performed with LY294002 (20 µM), PD98059 (20 µM), K-252A (300 nM) or rapamycin (20 nM), all from Calbiochem. Retroviral vectors encoding myristylated PKB and activated p110-CAAX PI(3)K were gifts from F. Scheeren and J. Collard respectively.
Paraffin-embedded tissue was cut into 4-µm sections, deparaffinized and rehydrated. Upon antigen retrieval performed with citrate buffer (pH, 6) and incubation with primary and secondary antibodies, immunocomplexes were detected with either DAB/H2O2 or AEC (Dakocytomation).
For western blotting and immunohistochemistry, the following antibodies were used: MS-862 for MCM-7 (NeoMarkers); AC-74 for actin (Sigma); 9661 for cleaved caspase-3 and 9202 for p70S6K (Cell Signalling); SC-8316 for TrkB, SC-260 for CDK4, SC-7985 for Ser 473-phosphorylated PKB and SC-8312 for PKB (all Santa Cruz).
In vivo assays
To determine tumorigenicity and metastatic potential, the RIE cell panel (1 × 106 cells) was injected subcutaneously into athymic nude mice in each flank. Mice were inspected daily and were killed at the time tumours reached a diameter of 10 mm.
To measure metastatic potential and allow in-vivo bioluminescence luciferase imaging, mice were injected intravenously with the RIE cell panel (1 × 106 for Fig. 3b, c, and 3 × 106 for Fig. 3a; administration of 107 cells gave identical results; not shown), co-expressing a luciferase gene and cDNAs of interest. In vivo bioluminescence imaging of luciferase expression was performed as described21. Generally, for each cell line, 2–4 mice were imaged in time, with similar results.
Frisch, S. M. & Ruoslahti, E. Integrins and anoikis. Curr. Opin. Cell Biol. 9, 701–706 (1997)
Frisch, S. M. & Screaton, R. A. Anoikis mechanisms. Curr. Opin. Cell Biol. 13, 555–562 (2001)
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000)
Klein, R., Parada, L. F., Coulier, F. & Barbacid, M. trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development. EMBO J. 8, 3701–3709 (1989)
Huang, E. J. & Reichardt, L. F. Trk receptors: roles in neuronal signal transduction. Annu. Rev. Biochem. 72, 609–642 (2003)
Shao, J., Sheng, H., DuBois, R. N. & Beauchamp, R. D. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J. Biol. Chem. 275, 22916–22924 (2000)
McFall, A. et al. Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase. Mol. Cell Biol. 21, 5488–5499 (2001)
Koh, E. Y., Chen, T. & Daley, G. Q. Novel retroviral vectors to facilitate expression screens in mammalian cells. Nucleic Acids Res. 30, e142 (2002)
Glass, D. J. et al. TrkB mediates BDNF/NT-3-dependent survival and proliferation in fibroblasts lacking the low affinity NGF receptor. Cell 66, 405–413 (1991)
Jaboin, J., Hong, A., Kim, C. J. & Thiele, C. J. Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma. Cancer Lett. 193, 109–114 (2003)
Ho, R. et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res. 62, 6462–6466 (2002)
Klein, R. et al. Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death. Cell 75, 113–122 (1993)
Banks, G. B. & Noakes, P. G. Elucidating the molecular mechanisms that underlie the target control of motoneuron death. Int. J. Dev. Biol. 46, 551–558 (2002)
Soppet, D. et al. The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. Cell 65, 895–903 (1991)
Squinto, S. P. et al. trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. Cell 65, 885–893 (1991)
Ruoslahti, E. & Vaheri, A. Cell-to-cell contact and extracellular matrix. Curr. Opin. Cell Biol. 9, 605–607 (1997)
Reginato, M. J. et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nature Cell Biol. 5, 733–740 (2003)
Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H. & Downward, J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 16, 2783–2793 (1997)
Schmidt, M., Hovelmann, S. & Beckers, T. L. A novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosis. Br. J. Cancer 87, 924–932 (2002)
Wendel, H. G. et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332–337 (2004)
Vooijs, M., Jonkers, J., Lyons, S. & Berns, A. Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumours in mice. Cancer Res. 62, 1862–1867 (2002)
Nakagawara, A., Azar, C. G., Scavarda, N. J. & Brodeur, G. M. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol. Cell Biol. 14, 759–767 (1994)
Aoyama, M. et al. Human neuroblastomas with unfavorable biologies express high levels of brain-derived neurotrophic factor mRNA and a variety of its variants. Cancer Lett. 164, 51–60 (2001)
Eggert, A. et al. Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. J. Clin. Oncol. 19, 689–696 (2001)
Brodeur, G. M. Neuroblastoma: biological insights into a clinical enigma. Nature Rev. Cancer 3, 203–216 (2003)
Bardelli, A. et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300, 949 (2003)
Bernards, R. & Weinberg, R. A. A progression puzzle. Nature 418, 823 (2002)
Ruggeri, B. A., Miknyoczki, S. J., Singh, J. & Hudkins, R. L. Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models. Curr. Med. Chem. 6, 845–857 (1999)
Peeper, D. S. et al. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nature Cell Biol. 4, 148–153 (2002)
Zamzami, N. et al. Mitochondrial control of nuclear apoptosis. J. Exp. Med. 183, 1533–1544 (1996)
We thank M. van der Valk and J.-Y. Song for help with animal pathology and experiments; E. Mesman, J. Bulthuis, K. de Goeij and M. Tjin-a-Koeng for histotechnical analysis; and L. Rijswijk, F. van der Ahé, H. Grimminck and L. Tolkamp for help with oncogenicity experiments and animal husbandry. We thank E. Koh and G. Daley for providing pEYK libraries; R. Beauchamp for RIE cells; K. Berns, B. Burgering, E. Danen, R. van der Kammen, R. Kortlever, S. Lens, F. Scheeren, S. Tait, E. de Vries and A. Werner for various reagents; R. Bernards, J. Borst, J. Collard, J. Hilkens, W. Mooi, E. Roos, A. Sonnenberg, as well as the members of our laboratory and division, for helpful discussions; and M. van Lohuizen and A. Berns for suggestions and critical reading of the manuscript. D.S.P. and T.L. were supported by the Netherlands Organization for Scientific Research (NWO).
The authors declare that they have no competing financial interests.
Suppression of anoikis by TrkB. (PPT 1500 kb)
TrkB downstream signaling in anoikis suppression. (PPT 4074 kb)
Overview of tumor spectrum and latencies induced by TrkB upon intravenous injection. (PPT 23 kb)
Invasive and metastasizing character induced by TrkB upon intravenous injection. (PPT 1577 kb)
Tumorigenicity induced by TrkB upon subcutaneous injection. (PPT 22 kb)
About this article
Cite this article
Douma, S., van Laar, T., Zevenhoven, J. et al. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430, 1034–1039 (2004). https://doi.org/10.1038/nature02765
Signal Transduction and Targeted Therapy (2022)
The prognostic value of circulating tumour cells (CTCs) and CTC white blood cell clusters in patients with renal cell carcinoma
BMC Cancer (2021)
British Journal of Cancer (2021)
Scientific Reports (2021)
Hepatic metastasis of gastric cancer is associated with enhanced expression of ethanolamine kinase 2 via the p53–Bcl-2 intrinsic apoptosis pathway
British Journal of Cancer (2021)